Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Programmed Cell Death 1 Ligand 1(PDL1, PD-L1)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT05809336
What this trial is testing

Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor
Beijing Friendship Hospital 172
Early research (Phase 1)Looking for participantsNCT07619313
What this trial is testing

AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer

Who this might be right for
Borderline Resectable Pancreatic Ductal AdenocarcinomaLocally Advanced CholangiocarcinomaLocally Advanced Pancreatic Adenocarcinoma+5 more
Jonsson Comprehensive Cancer Center 46
Not applicableUnknownNCT03652142
What this trial is testing

Predictive Biomarkers for Response to Nivolumab in Head and Neck Squamous Cell Carcinoma

Who this might be right for
HNSCCDNA DamageDNA Double Strand Break
Attikon Hospital 50
Testing effectiveness (Phase 2)Study completedNCT03390296
What this trial is testing

OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center 50
Testing effectiveness (Phase 2)Looking for participantsNCT07269782
What this trial is testing

A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Shanghai Henlius Biotech 60
Large-scale testing (Phase 3)Ended earlyNCT04746924
What this trial is testing

Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

Who this might be right for
Non-small Cell Lung CancerNSCLC
BeiGene 669
Testing effectiveness (Phase 2)Active Not RecruitingNCT02846623
What this trial is testing

Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome

Who this might be right for
Chronic Lymphocytic LeukemiaRecurrent Transformed Chronic Lymphocytic LeukemiaRefractory Transformed Chronic Lymphocytic Leukemia+2 more
M.D. Anderson Cancer Center 50
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06946836
What this trial is testing

Comparison of Neoadjuvant Cadonilimab Versus Chemotherapy Combined With PD-1 in the Treatment of Resectable Non-Small Cell Lung Cancer With High PD-L1 Expression: A Single-Center, Randomized, Exploratory Clinical Study

Who this might be right for
Resectable Non-small Cell Lung CancerBispecific AntibodyNeoadjuvant Therapy
Shanghai Pulmonary Hospital, Shanghai, China 80
Testing effectiveness (Phase 2)UnknownNCT03399071
What this trial is testing

Study Title: Peri-operative Immuno-Chemotherapy in Operable Oesophageal and Gastric Cancer

Who this might be right for
Gastric AdenocarcinomaOesophageal Adenocarcinoma
Royal Marsden NHS Foundation Trust 44
Testing effectiveness (Phase 2)Study completedNCT02423863
What this trial is testing

In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®

Who this might be right for
MelanomaHead and Neck CancerSarcoma+1 more
Oncovir, Inc. 26
Testing effectiveness (Phase 2)Looking for participantsNCT06441747
What this trial is testing

Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

Who this might be right for
Cholangiocarcinoma
Australasian Gastro-Intestinal Trials Group 40
Large-scale testing (Phase 3)Study completedNCT04716933
What this trial is testing

Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study

Who this might be right for
Nonsquamous Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC 201
Testing effectiveness (Phase 2)Study completedNCT03463681
What this trial is testing

CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma

Who this might be right for
Metastatic Renal Cell Carcinoma
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 49
Large-scale testing (Phase 3)Active Not RecruitingNCT05690945
What this trial is testing

QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer

Who this might be right for
Lung Cancer
Qilu Pharmaceutical Co., Ltd. 606
Testing effectiveness (Phase 2)Study completedNCT04875195
What this trial is testing

Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)

Who this might be right for
Hodgkin's LymphomaPrimary Mediastinal Large B-cell Lymphoma (PMBCL)
Merck Sharp & Dohme LLC 66
Large-scale testing (Phase 3)Active Not RecruitingNCT05374512
What this trial is testing

Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

Who this might be right for
Breast Cancer
AstraZeneca 644
Testing effectiveness (Phase 2)WithdrawnNCT05539365
What this trial is testing

Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+1 more
Roswell Park Cancer Institute
Testing effectiveness (Phase 2)Study completedNCT04704219
What this trial is testing

Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)

Who this might be right for
Renal Cell Carcinoma
Merck Sharp & Dohme LLC 160
Large-scale testing (Phase 3)Study completedNCT03515837
What this trial is testing

Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)

Who this might be right for
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC 492
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06842472
What this trial is testing

PD-L1 Inhibitor + RT ± Ursodeoxycholic Acid in Recurrent/Metastatic HER2-Neg Breast Cancer

Who this might be right for
Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 70
Next Page